Access to Quality-assured Artemisinin-based Combination Therapy and Associated Factors Among Clients of Selected Private Drug Outlets in Uganda

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2024 Apr 30

PMID 38689257

Authors

Moses Ocan

Loyce Nakalembe

Caroline Otike

Tayebwa Mordecai

Joan Birungi

Sam Nsobya

Affiliations

Soon will be listed here.

Abstract

Background: Malaria treatment in sub-Saharan Africa is faced with challenges including unreliable supply of efficacious agents, substandard medicines coupled with high price of artemisinin-based combinations. This affects access to effective treatment increasing risk of malaria parasite resistance development and adverse drug events. This study investigated access to quality-assured artemisinin-based combination therapy (QAACT) medicines among clients of selected private drug-outlets in Uganda.

Methods: This was a cross sectional study where exit interviews were conducted among clients of private drug outlets in low and high malaria transmission settings in Uganda. This study adapted the World Health Organization/Health Action International (WHO/HAI) standardized criteria. Data was collected using a validated questionnaire. Data entry screen with checks was created in Epi-data ver 4.2 software and data entered in duplicate. Data was transferred to STATA ver 14.0 and cleaned prior to analysis. The analysis was done at 95% level of significance.

Results: A total of 1114 exit interviews were conducted among systematically sampled drug outlet clients. Over half, 54.9% (611/1114) of the participants were males. Majority, 97.2% (1083/1114) purchased an artemisinin-based combination anti-malarial. Most, 55.5% (618/1114) of the participants had a laboratory diagnosis of malaria. Majority, 77.9% (868/1114) of the participants obtained anti-malarial agents without a prescription. Less than a third, 27.7% (309/1114) of the participants obtained a QAACT. Of the participants who obtained QAACT, more than half 56.9% (173/309) reported finding the medicine expensive. The predictors of accessing a QAACT anti-malarial among drug outlet clients include type of drug outlet visited (aPR = 0.74; 95%CI 0.6, 0.91), not obtaining full dose (3-day treatment) of ACT (aPR = 0.49; 95%CI 0.33, 0.73), not finding the ACT expensive (aPR = 1.24; 95%CI 1.03, 1.49), post-primary education (aPR = 1.29; 95%CI 1.07,1.56), business occupation (aPR = 1.24; 95%CI 1.02,1.50) and not having a prescription (aPR = 0.76; 95%CI 0.63, 0.92).

Conclusion: Less than a third of the private drug outlet clients obtained a QAACT for management of malaria symptoms. Individuals who did not find artemisinin-based combinations to be expensive were more likely to obtain a QAACT anti-malarial. The Ministry of Health needs to conduct regular surveillance to monitor accessibility of QAACT anti-malarial agents under the current private sector copayment mechanism.

References

Goodman C, Brieger W, Unwin A, Mills A, Meek S, Greer G . Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved?. Am J Trop Med Hyg. 2008; 77(6 Suppl):203-18. PMC: 2657822. View

Dondorp A, Yeung S, White L, Nguon C, Day N, Socheat D . Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010; 8(4):272-80. DOI: 10.1038/nrmicro2331. View

Pulford J, Siba P, Mueller I, Hetzel M . The exit interview as a proxy measure of malaria case management practice: sensitivity and specificity relative to direct observation. BMC Health Serv Res. 2014; 14:628. PMC: 4259085. DOI: 10.1186/s12913-014-0628-8. View

Tougher S, Hanson K, Goodman C . What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism. Malar J. 2017; 16(1):173. PMC: 5405529. DOI: 10.1186/s12936-017-1814-z. View

Asua V, Conrad M, Aydemir O, Duvalsaint M, Legac J, Duarte E . Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. J Infect Dis. 2020; 223(6):985-994. PMC: 8006419. DOI: 10.1093/infdis/jiaa687. View

Kibira D, Ssebagereka A, van den Ham H, Opigo J, Katamba H, Seru M . Trends in access to anti-malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first-line anti-malarials and diagnostics between 2007 and 2018. Malar J. 2021; 20(1):142. PMC: 7944888. DOI: 10.1186/s12936-021-03680-8. View

Nanyunja M, Orem J, Kato F, Kaggwa M, Katureebe C, Saweka J . Malaria treatment policy change and implementation: the case of Uganda. Malar Res Treat. 2012; 2011:683167. PMC: 3265287. DOI: 10.4061/2011/683167. View

Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I . Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries. Health Policy Plan. 2015; 31(2):148-60. PMC: 4748126. DOI: 10.1093/heapol/czv031. View

Ocan M, Bwanga F, Bbosa G, Bagenda D, Waako P, Ogwal-Okeng J . Patterns and predictors of self-medication in northern Uganda. PLoS One. 2014; 9(3):e92323. PMC: 3962384. DOI: 10.1371/journal.pone.0092323. View

10.

Tougher S, Ye Y, Amuasi J, Kourgueni I, Thomson R, Goodman C . Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet. 2012; 380(9857):1916-26. DOI: 10.1016/S0140-6736(12)61732-2. View

11.

Davis B, Ladner J, Sams K, Tekinturhan E, de Korte D, Saba J . Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries. Malar J. 2013; 12:135. PMC: 3637826. DOI: 10.1186/1475-2875-12-135. View

12.

Balikagala B, Fukuda N, Ikeda M, Katuro O, Tachibana S, Yamauchi M . Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med. 2021; 385(13):1163-1171. DOI: 10.1056/NEJMoa2101746. View

13.

Tougher S, Mann A, Ye Y, Kourgueni I, Thomson R, Amuasi J . Improving access to malaria medicine through private-sector subsidies in seven African countries. Health Aff (Millwood). 2014; 33(9):1576-85. DOI: 10.1377/hlthaff.2014.0104. View

14.

Leurent B, Reyburn H, Muro F, Mbakilwa H, Schellenberg D . Monitoring patient care through health facility exit interviews: an assessment of the Hawthorne effect in a trial of adherence to malaria treatment guidelines in Tanzania. BMC Infect Dis. 2016; 16:59. PMC: 4739341. DOI: 10.1186/s12879-016-1362-0. View

15.

Newton P, Caillet C, Guerin P . A link between poor quality antimalarials and malaria drug resistance?. Expert Rev Anti Infect Ther. 2016; 14(6):531-3. DOI: 10.1080/14787210.2016.1187560. View

16.

Trape J, Pison G, Preziosi M, Enel C, Desgrees du Lou A, Delaunay V . Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998; 321(8):689-97. DOI: 10.1016/s0764-4469(98)80009-7. View